La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Perspective Therapeutics Gestione

Gestione criteri di controllo 1/4

Perspective Therapeutics' Il CEO è Thijs Spoor, nominato in Feb2023, e ha un mandato di 1.5 anni. la retribuzione annua totale è $ 1.46M, composta da 34.7% di stipendio e 65.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.031% delle azioni della società, per un valore di $ 279.97K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.5 anni e 1.5 anni.

Informazioni chiave

Thijs Spoor

Amministratore delegato

US$1.5m

Compenso totale

Percentuale dello stipendio del CEO	34.7%
Mandato del CEO	1.5yrs
Proprietà del CEO	0.03%
Durata media del management	1.5yrs
Durata media del Consiglio di amministrazione	1.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Thijs Spoor rispetto agli utili di Perspective Therapeutics?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$52m
Mar 31 2024	n/a	n/a	-US$50m
Dec 31 2023	US$1m	US$506k	-US$37m

Compensazione vs Mercato: La retribuzione totale di Thijs ($USD 1.46M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 3.30M ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Thijs con le performance aziendali.

AMMINISTRATORE DELEGATO

Thijs Spoor (52 yo)

1.5yrs

Mandato

US$1,458,996

Compensazione

Mr. Johan M. Spoor, also known as Thijs, is Chief Executive Officer and Director at Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) since February 05, 2023. He founded AzurRx BioPharma, Inc...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Johan Spoor	CEO & Director	1.5yrs	US$1.46m	0.031% $ 318.0k
Jonathan Hunt	CFO & Co-Principal Financial Officer	5.7yrs	US$1.17m	0.053% $ 551.1k
Markus Puhlmann	Chief Medical Officer	1.5yrs	US$900.09k	0.20% $ 2.1m
Shane Cobb	Executive Vice President of Operations	less than a year	Nessun dato	Nessun dato
Mark Austin	VP of Finance	7.1yrs	Nessun dato	0.012% $ 128.7k
Michael Schultz	Chief Science Officer	no data	Nessun dato	2.2% $ 22.7m
Andrew Bright	Executive Vice President of Brachytherapy	1.3yrs	Nessun dato	Nessun dato
Amos Hedt	Chief Business Strategy Officer	no data	Nessun dato	Nessun dato
Frances Johnson	Chief Innovation Officer	no data	Nessun dato	2.2% $ 22.7m
David Hauser	Senior Vice President of Clinical Operations	no data	Nessun dato	Nessun dato

1.5yrs

Durata media

54.5yo

Età media

Gestione esperta: Il team dirigenziale di CATX non è considerato esperto (durata media 1.5 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Johan Spoor	CEO & Director	1.5yrs	US$1.46m	0.031% $ 318.0k
Robert Williamson	Independent Director	1.5yrs	US$320.06k	0.063% $ 654.9k
Frank Morich	Independent Director	1.5yrs	US$320.06k	Nessun dato
Heidi Henson	Independent Director	1.2yrs	US$390.70k	Nessun dato
Lori Holmes-Woods	Chairperson of the Board	6.2yrs	US$671.73k	0.24% $ 2.5m

1.5yrs

Durata media

58yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di CATX non è considerato esperto (durata media del mandato 1.5 anni), il che suggerisce un nuovo consiglio.

Perspective Therapeutics Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

CFO & Co-Principal Financial Officer recently bought US$177k worth of stock

CEO & Director recently bought US$117k worth of stock

Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024

Chief Medical Officer recently bought US$140k worth of stock

Chief Medical Officer recently bought US$189k worth of stock

Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023

Recent updates

Consensus revenue estimates increase by 51%, EPS downgraded

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $49.868808 million.

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Perspective Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

CFO & Co-Principal Financial Officer recently bought US$177k worth of stock

CEO & Director recently bought US$117k worth of stock

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $79.998535 million.

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Perspective Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings released: US$0.14 loss per share (vs US$0.10 loss in FY 2022)

Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024

Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc.

Perspective Therapeutics, Inc. announced that it expects to receive $87.409482 million in funding from Lantheus Holdings, Inc. and other investors

Perspective Therapeutics, Inc. (NYSEAM:CATX) completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.

Perspective Therapeutics, Inc. Introduces Pre-Targeting Theranostic Technology Platform

Chief Medical Officer recently bought US$140k worth of stock

Forecast to breakeven in 2026

Perspective Therapeutics, Inc. announced that it has received $20.846671 million in funding from Lantheus Alpha Therapy, LLC

Perspective Therapeutics, Inc. announced that it expects to receive $20.8 million in funding

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering.

Chief Medical Officer recently bought US$189k worth of stock

Perspective Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Study Of212pb)Vmt-A-Net to Treat Refractory or Relapsed Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces First Ever Human SPECT Imaging of Pb-212 with VMT-a-NET by Clinical Collaborators in Germany

Perspective Therapeutics, Inc. Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals

New major risk - Financial position

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2A Study of [(212)Pb VMT-a-Net for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces Two Upcoming Investigator-Initiated Trials

Perspective Therapeutics, Inc. Announces Presentation of Positive Early Clinical Data for VMT-a-NET at 36th Annual Congress of European Association of Nuclear Medicine

Perspective Therapeutics, Inc. Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023

New major risk - Financial position

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma

Second quarter 2023 earnings released

Perspective Therapeutics, Inc. Announces Termination of Jennifer Streeter as Chief Operating Officer

Less than half of directors are independent

Perspective Therapeutics, Inc.'s Cesium-131 Features at the American Brachytherapy Society's Annual Conference

Perspective Therapeutics, Inc. Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates

Less than half of directors are independent

Perspective Therapeutics, Inc. Announces Changes to the Board of Directors

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.009 loss in 1Q 2022)

Chairperson of the Board exercised options to buy US$129k worth of stock.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Isoray, Inc. Announces Termination of William Cavanagh III as Chief Research and Development Officer

Isoray, Inc. Announces Executive Changes

Isoray, Inc., Annual General Meeting, Jan 12, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Isoray, Inc. to Report Q1, 2023 Results on Nov 10, 2022

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Isoray, Inc. (NYSEAM:ISR) entered into an Agreement and Plan of Merger to acquire Viewpoint Molecular Targeting, Inc.

Isoray, Inc. to Report Q4, 2022 Results on Sep 28, 2022

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media